Literature DB >> 2366881

High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.

W Löscher1, D Hönack.   

Abstract

Memantine (1-amino-3,5-dimethyladamantane) has previously been shown to attenuate or block chemically or electrically induced seizures in rodents at doses of 5-20 mg/kg i.p., suggesting that the drug might have potential utility in the treatment of seizures. In the present study, the effects of memantine were examined in amygdala-kindled and non-kindled rats. In fully kindled rats, i.e. a model of focal seizures with secondary generalization, memantine exerted no effects on seizure parameters at 5 mg/kg i.p., but reduced seizure severity and duration at 10 mg/kg. The threshold for induction of afterdischarges recorded from the amygdala was not altered after administration of 10 mg/kg. At 20 mg/kg, memantine induced spontaneous motor seizures in amygdala-kindled rats. No motor seizures were observed in non-kindled rats, but in both kindled and non-kindled animals memantine, 20 mg/kg, induced spikes in the electroencephalogram. Additional dose-dependent behavioural alterations observed after memantine included hyperactivity, ataxia and stereotypies, which may relate to the dopaminomimetic properties of the drug. The results demonstrate that kindled rats are more sensitive to central nervous system stimulating effects of memantine than non-kindled rats, which could relate to an impairment of inhibitory processes and/or alterations in synaptic transmission mediated by excitatory amino acids in the kindled brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2366881     DOI: 10.1007/bf00176343

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative.

Authors:  T H Svensson
Journal:  Eur J Pharmacol       Date:  1973-09       Impact factor: 4.432

2.  [Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].

Authors:  E Schneider; P A Fischer; R Clemens; F Balzereit; E W Fünfgeld; H J Haase
Journal:  Dtsch Med Wochenschr       Date:  1984-06-22       Impact factor: 0.628

3.  [Effect of memantine on central neurotransmitter systems. Review of the results].

Authors:  J Maj
Journal:  Arzneimittelforschung       Date:  1982

Review 4.  Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review.

Authors:  W Löscher
Journal:  Methods Find Exp Clin Pharmacol       Date:  1984-09

5.  Kindling induced changes in EEG recorded during stimulation from the site of stimulation: collapse of GABA-mediated inhibition and onset of rhythmic synchronous burst.

Authors:  K Morimoto; G V Goddard
Journal:  Exp Neurol       Date:  1986-12       Impact factor: 5.330

6.  Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice.

Authors:  Z Kleinrok; S J Czuczwar; M Kozicka
Journal:  Epilepsia       Date:  1980-10       Impact factor: 5.864

7.  Decrease in GABA immunoreactivity and alteration of GABA metabolism after kindling in the rat hippocampus.

Authors:  W Kamphuis; E Huisman; W J Wadman; F H Lopes da Silva
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

8.  Pharmacological investigation of convulsant gamma-aminobutyric acid (GABA) antagonists in amygdala-kindled rats.

Authors:  M W Kalichman
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

9.  Evidence for impaired GABAergic activity in the substantia nigra of amygdaloid kindled rats.

Authors:  W Löscher; W S Schwark
Journal:  Brain Res       Date:  1985-07-22       Impact factor: 3.252

10.  [Valve of symptomatic therapy with memantine in cerebral coma. II. Development of stretch synergisms in coma with brain stem symptoms].

Authors:  F O Miltner
Journal:  Arzneimittelforschung       Date:  1982
View more
  7 in total

1.  Effects of ionotropic glutamate receptor channel blockers on the development of pentylenetetrazol kindling in mice.

Authors:  N Ya Lukomskaya; V V Lavrent'eva; L A Starshinova; E P Zhabko; L V Gorbunova; T B Tikhonova; V E Gmiro; L G Magazanik
Journal:  Neurosci Behav Physiol       Date:  2007-01

Review 2.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

3.  Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.

Authors:  W Löscher; P Wlaź; C Rundfeldt; H Baran; D Hönack
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 4.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

Review 5.  Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Manuel Merlos; Javier Garzón-Niño
Journal:  Oncotarget       Date:  2016-08-23

6.  Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Javier Garzón
Journal:  Oncotarget       Date:  2018-05-04

Review 7.  Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia.

Authors:  Michal Rychlik; Katarzyna Mlyniec
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.